Weekly Recap: Guidance extension to 2031 and remibrutinib Phase III success
Novartis AG (SIX:NOVN) navigates a mixed outlook: CEO Vas Narasimhan expects faster sales growth and may extend guidance, while clinical wins for remibrutinib and a positive Cosentyx opinion contrast with late—stage setbacks and a sharp Entresto US sales decline after generics.Previous Week RecapTh…